Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products

Neuropsychopharmacology

Volumn 38, Issue 4, 2013, Pages 552-562

  Baumann, Michael H ^a   Partilla, John S ^a   Lehner, Kurt R ^a   Thorndike, Eric B ^a   Hoffman, Alexander F ^a   Holy, Marion ^b   Rothman, Richard B ^a   Goldberg, Steven R ^a   Lupica, Carl R ^a   Sitte, Harald H ^b   Brandt, Simon D ^c   Tella, Srihari R ^d   Cozzi, Nicholas V ^e   Schindler, Charles W ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^d Drug Enforcement Administration   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

cathinone; designer drug; dopamine; monoamine transporter; uptake blocker

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; CATHINONE; COCAINE; DOPAMINE; NORADRENALIN; SEROTONIN; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN SLICE; BRAIN SYNAPTOSOME; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORPUS STRIATUM; CYCLIC POTENTIOMETRY; DRUG EFFICACY; DRUG POTENCY; HYPERTENSION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; TACHYCARDIA;

ANIMALS; BENZODIOXOLES; COCAINE; CORPUS STRIATUM; DESIGNER DRUGS; DOPAMINE; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; ORGAN CULTURE TECHNIQUES; PSYCHOTROPIC DRUGS; PYRROLIDINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SALTS;

EID: 84873742824     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.204     Document Type: Article

References (54)

1. Baumann MH, Ayestas MA Jr., Partilla JS, Sink JR, Shulgin AT, Daley PF et al (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
2. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB 2011). In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337: 218-225.
3. Baumann MH, Wang X, Rothman RB (2007). 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189: 407-424.
4. Bonci A, Bernardi G, Grillner P, Mercuri NB (2003). The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci 24: 172-177.
5. Borek HA, Holstege CP (2012). Hyperthermia and multiorgan failure after abuse of 'bath salts' containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 60: 103-105.
6. Bull DR, Palij P, Sheehan MJ, Millar J, Stamford JA, Kruk ZL et al (1990). Application of fast cyclic voltammetry to measurement of electrically evoked dopamine overflow from brain slices in vitro. J Neurosci Methods 32: 37-44.
7. Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA (2012). Designer drugs: a medicinal chemistry perspective. Ann NY Acad Sci 1248: 18-38.
8. Chen YH, Harvey BK, Hoffman AF, Wang Y, Chiang YH, Lupica CR (2008). MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. FASEB J 22: 261-275.
9. Cozzi NV, Sievert MK, Shulgin AT, Jacob P III., Ruoho AE (1999). Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381: 63-69.
10. Drug Enforcement Administration 2011). Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order. In: Fed Regist Vol. 76, 2011/10/25 edn, pp 65371-65375.
11. Fauquet JP, Morel E, Demarty C, Rapin JR (1976). [Role of central catecholamines in the psychostimulant activity of pyrovalerone]. Arch Int Pharmacodyn Ther 224: 325-337.
12. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007). New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681-698.
13. Goldberg J, Gardos G, Cole JO (1973). A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int Pharmacopsychiatry 8: 60-69.
14. Good CH, Hoffman AF, Hoffer BJ, Chefer VI, Shippenberg TS, Backman CM et al 2011). Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB J 25: 1333-1344.
15. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC et al 2011). 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
16. Halberstadt AL, Buell MR, Price DL, Geyer MA (2012). Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats. Pharmacol Biochem Behav 102: 88-94.
17. Heron C, Costentin J, Bonnet JJ (1994). Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur J Pharmacol 264: 391-398.
18. Hill SL, Thomas SH 2011). Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 49: 705-719.
19. Holliday AR, Morris RB, Sharpley RP (1964). Compound 84/F 1983 compared with D-amphetamine and placebo in regard to effects on human performance. Psychopharmacologia 6: 192-200.
20. Huang PK, Aarde SM, Angrish D, Houseknecht KL, Dickerson TJ, Taffe MA (2012). Contrasting effects of d-methamphetamine, 3,4- methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend (in press).
21. Hyland BI, Reynolds JN, Hay J, Perk CG, Miller R (2002). Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience 114: 475-492.
22. Ikemoto S (2002). Ventral striatal anatomy of locomotor activity induced by cocaine, D-amphetamine, dopamine and D1/D2 agonists. Neuroscience 113: 939-955.
23. John CE, Jones SR (2007). Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudateputamen and substantia nigra slices. Neuropharmacology 52: 1596-1605.
24. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F et al 2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 1949-1958.
25. Kyle PB, Iverson RB, Gajagowni RG, Spencer L 2011). Illicit bath salts: not for bathing. J Miss State Med Assoc 52: 375-377.
26. Martinez-Clemente J, Escubedo E, Pubill D, Camarasa J 2011). Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22: 231-236.
27. Mash DC, Duque L, Pablo J, Qin Y, Adi N, Hearn WL et al (2009). Brain biomarkers for identifying excited delirium as a cause of sudden death. Forensic Sci Int 190: e13-e19.
28. Meltzer PC, Butler D, Deschamps JR, Madras BK (2006). 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49: 1420-1432.
29. Mollenhauer HH, Morre DJ, Rowe LD (1990). Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim Biophys Acta 1031: 225-246.
30. Murray BL, Murphy CM, Beuhler MC (2012). Death following recreational use of designer drug 'bath salts' containing 3,4-Methylenedioxypyrovalerone (MDPV). J Med Toxicol 8: 69-75.
31. Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559: 132-137.
32. Pennartz CM, Groenewegen HJ, Lopes da Silva FH (1994). The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog Neurobiol 42: 719-761.
33. Psychonaut Web Mapping Group (2009). MDPV Report. edn Institute of Psychiatry, Kings College, London: London, UK.
34. Ross EA, Watson M, Goldberger B 2011). 'Bath salts' intoxication. N Engl J Med 365: 967-968.
35. Rothman RB, Baumann MH (2003a). Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479: 23-40.
36. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
37. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA et al (2003b). In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307: 138-145.
38. Ruttenber AJ, Lawler-Heavner J, Yin M, Wetli CV, Hearn WL, Mash DC (1997). Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity. J Forensic Sci 42: 25-31.
39. Schindler CW, Carmona GN (2002). Effects of dopamine agonists and antagonists on locomotor activity in male and female rats. Pharmacol Biochem Behav 72: 857-863.
40. Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D (2001). Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci 21: 5916-5924.
41. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH (2000). Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther 293: 870-878.
42. Shanks KG, Dahn T, Behonick G, Terrell A (2012). Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 36: 360-371.
43. Sitte HH, Freissmuth M (2010). The reverse operation of Na(\+)/Cl(-)-coupled neurotransmitter transporters-why amphetamines take two to tango. J Neurochem 112: 340-355.
44. Sogawa C, Sogawa N, Ohyama K, Kikura-Hanajiri R, Goda Y, Sora I et al 2011). Methylone and monoamine transporters: correlation with toxicity. Curr Neuropharmacol 9: 58-62.
45. Spiller HA, Ryan ML, Weston RG, Jansen J 2011). Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin Toxicol (Phila) 49: 499-505.
46. Sucic S, Dallinger S, Zdrazil B, Weissensteiner R, Jorgensen TN, Holy M et al (2010). The N terminus of monoamine transporters is a lever required for the action of amphetamines. J Biol Chem 285: 10924-10938.
47. Tella SR, Schindler CW, Goldberg SR (1999). Cardiovascular responses to cocaine self-administration: acute and chronic tolerance. Eur J Pharmacol 383: 57-68.
48. Tidjane Corera A, Do-Rego JC, Costentin J, Bonnet JJ (2001). Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes. Neurosci Res 39: 319-325.
49. Turetta L, Donella-Deana A, Folda A, Bulato C, Deana R (2004). Characterisation of the serotonin efflux induced by cytosolic Ca2\+ and Na\+ concentration increase in human platelets. Cell Physiol Biochem 14: 377-386.
50. Vaugeois JM, Bonnet JJ, Duterte-Boucher D, Costentin J (1993). In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol 230: 195-201.
51. Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF et al (2012). Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol (in press).
52. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL (2005). Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313: 848-854.
53. Willuhn I, Wanat MJ, Clark JJ, Phillips PE (2010). Dopamine signaling in the nucleus accumbens of animals selfadministering drugs of abuse. Curr Top Behav Neurosci 3: 29-71.
54. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V et al (2009). Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738-746.